Skip to main
NAGE

ChromaDex Corp (NAGE) Stock Forecast & Price Target

ChromaDex Corp (NAGE) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Niagen Bioscience is a leader in NAD+ science and healthy aging research, with clinically proven products that efficiently increase NAD+ levels. The company recently reported strong 1Q26 financial results, with moderate revenue outperformance and in-line earnings. They have a well-established product portfolio and a favorable market outlook, with projected sales growth in the anti-aging and longevity markets. Risks include slower sales growth, unfavorable clinical data, and increased competition, but potential opportunities such as a pen-like autoinjector and ongoing research in NAD+ related diseases could drive future growth. Overall, Niagen Bioscience presents an attractive investment opportunity with a strong brand reputation and focus on innovation in the health and wellness sector.

Bears say

Niagen Bioscience is a company that has yet to produce a successful product in the market despite its promising technology and research in NAD+ boosting solutions. The company's low probability of getting their products on the market and high discount rate contribute to a negative outlook as it raises concerns about their ability to generate revenue and reach profitability. Their estimated enterprise value of $393M also does not fully justify the risks associated with investing in this company.

ChromaDex Corp (NAGE) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ChromaDex Corp (NAGE) Forecast

Analysts have given ChromaDex Corp (NAGE) a Strong Buy based on their latest research and market trends.

According to 3 analysts, ChromaDex Corp (NAGE) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ChromaDex Corp (NAGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.